Innogenetics, Abbott Strike $9.5M Deal On HCV Patent
Innogenetics NV has struck a $9.5 million settlement and licensing agreement with Abbott Laboratories that resolves a long-standing patent dispute between the two companies over hepatitis C virus testing, the Belgian...To view the full article, register now.
Already a subscriber? Click here to view full article